

10/537851 #5

05 MAY 2006

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
RLI-270US

In Re Application Of: MEHTA et al.

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/537,851 | 12/10/2002 | TBA | 26815 | TBA | |

Title:

DISUBSTITUTED AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

BEST AVAILABLE COPY

P10A/REV05

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLI-270US

In Re Application of: MEHTA

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/537,851 | 12/10/2002 | TBA | 26815 | TBA | |

Title:

DISUBSTITUTED AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

| |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa |
| _____ (Date) |
| _____ Signature |
| _____ Typed or Printed Name of Person Signing Certificate |

Certificate of Mailing by ^{EXPRESS} First Class Mail

| |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class ^{EXPRESS} mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.0(a)] on <u>5/5/2006</u> . |
| _____ (Date) |
| <u>Michelle Morgan</u> Signature of Person Mailing Correspondence |
| <u>MICHELLE MORGAN</u> Typed or Printed Name of Person Mailing Certificate |

*This certificate may only be used if paying by deposit account.

George E. Heibel
Signature

Dated: May 5, 2006

George E. Heibel, Esq.
Reg. No. 42,648
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel.: 609 720-5334
Fax: 609 514-9779

cc:

| | | |
|----------------------------------------|-------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION | Docket No.: RLL-270US | Serial No.: 10/537,851 |
| | Applicants: MEH <i>et al.</i> | |
| | Filed: 6/8/2005 | Group: |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------------|------------------------|-------|----------|----------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | A1 | 3,176,019 | 3/30/1965 | Campbell <i>et al.</i> | 260 | 293.4 | |
| | A2 | 5,281,601 | 1/25/1994 | Cross <i>et al.</i> | 514 | 320 | |
| | A3 | 5,397,800 | 3/14/1995 | Alker <i>et al.</i> | 514 | 413 | |
| | A4 | 5,703,091 | 12/30/1997 | Steiner <i>et al.</i> | 514 | 300 | |
| | A5 | 5,914,338 | 6/22/1999 | Jeppesen <i>et al.</i> | 514 | 362 | |
| | A6 | 5,948,792 | 9/7/1999 | Tsuchiya <i>et al.</i> | 514 | 317 | |
| | A7 | 6,130,232 | 10/10/2000 | Mase <i>et al.</i> | 514 | 318 | |
| | A8 | 6,174,900 | 1/16/2001 | Okada <i>et al.</i> | 514 | 317 | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----|-----------------|------------|---------|-------|----------|--------------------------|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | B1 | EP 0 132 130 | 1/23/1985 | EPO | C07D | 307/79 | |
| | B2 | EP 0 325 571 | 7/26/1989 | EPO | C07C | 215/54 | |
| | B3 | EP 0 388 054 | 9/19/1990 | EPO | C07D | 207/08 | |
| | B4 | EP 0 801 067 | 10/15/1997 | EPO | C07D | 453/02 | |
| | B5 | EP 0 823 423 | 2/11/1998 | EPO | C07D | 211/46 | |
| | B6 | EP 0 863 141 | 9/9/1998 | EPO | C07D | 401/06 | |
| | B7 | EP 0 930 298 | 7/21/199 | EPO | C07D | 211/46 | |
| | B8 | GB 940,540 | 10/30/1963 | UK | C07C | | |
| | B9 | JP 135958/1994 | 5/17/1994 | Japan | C07D | 333/16 | |
| | B10 | JP 92921/1994 | 4/5/1994 | Japan | C07C | 237/20 | |
| | B11 | WO 91/09013 | 6/27/1991 | PCT | C07D | 207/08 | |
| | B12 | WO 93/16018 | 8/19/1993 | PCT | C05F | 17/02 | |
| | B13 | WO 93/16048 | 8/19/1993 | PCT | C07D | 211/26 | Equivalent CA 2155320 |

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | |

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-270US

Serial No.: 10/537,851

Applicants: MEH et al.

Filed: 6/8/2005

Group:

| | | | | | | | |
|--|-----|--------------|------------|-----|------|--------|----------------------------|
| | B14 | WO 96/33973 | 10/31/1996 | PCT | C07D | 211/46 | Equivalent EP 0 823 423 |
| | B15 | WO 97/45414 | 12/4/1997 | PCT | C07D | 211/58 | Abstract |
| | B16 | WO 98/05641 | 2/12/1998 | PCT | C07D | 211/46 | Equivalent US 5,948,792 |
| | B17 | WO 98/29402 | 7/9/1998 | PCT | C07D | 311/20 | |
| | B18 | WO 04/004629 | 1/15/2004 | PCT | A61K | | |
| | B19 | WO 04/005252 | 1/15/2004 | PCT | C07D | 209/52 | |
| | | | | | | | |


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | | | | | |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|
| | C1 | Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986) | | | | | |
| | C2 | Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987) | | | | | |
| | C3 | Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , 3:426-432 (1999) | | | | | |
| | C4 | Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001) | | | | | |
| | C5 | Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000) | | | | | |
| | C6 | Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , 6:142-193 (2001) | | | | | |
| | C7 | Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , 22(5):215-219 (2001) | | | | | |
| | C8 | de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , 41:691-721 (2001) | | | | | |
| | C9 | Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282 (2000) | | | | | |
| | C10 | Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , 55(Suppl. 5A):33-46 (2000) | | | | | |
| | C11 | Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996) | | | | | |
| | C12 | Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45:984-987 (2002) | | | | | |
| | C13 | Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.) | | | | | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|----------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION | Docket No.: RLL-270US | Serial No.: 10/537,851 |
| | Applicants: MEH  et al. | |
| | Filed: 6/8/2005 | Group: |

| | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| C14 | Braish et al., "Construction of the (1 α ,5 α ,6 α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996) |
| C15 | Vogel's textbook, "Practical Organic Chemistry" 1048-1051 (5th Ed.) |
| C16 | Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", <i>Journal of the American Chemical Society</i> , 75:2654-2657 (1953) |
| C17 | Gotteland et al., "(Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors", <i>Journal of Medicinal Chemistry</i> , 38:3207-3216 (1995) |
| C18 | Weinstock et al., "A General, One-Step Synthesis of α -keto Esters", <i>Synthetic Communications</i> , 11(12):943-946 (1981) |
| C19 | Cornforth et al., "General Synthetic Routes to β -Hydroxy-acids from t-Butyl Esters and the Reformatskii Reaction", <i>Journal of the Chemical Society C</i> , 20:2799-2805 (1969) |
| C20 | Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , 65:6283-6287 (2000) |
| C21 | Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , 64(25):2351-2358 (1999) |
| C22 | Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973) |
| | |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |